Literature DB >> 22180680

Diffuse large cell lymphoma presenting as a sacral mass and lupus anticoagulant.

Lilangi S Ediriwickrema1, Wajih Zaheer.   

Abstract

A 67-year-old gentleman presented to Yale-New Haven Hospital (YNHH) for assessment of a supratherapeutic INR and sacral lesion. Hematologic workup revealed elevated ESR, PT, INR, PTT, and CRP, mixing studies that failed to correct, and a positive Russell Viper Venom Test (RVVT), which confirmed the presence of lupus anticoagulant (LA), a subtype of antiphospholipid syndrome (APA). Pathology of the patient's sacral lesion revealed diffuse large B-cell lymphoma. This case provides insight into the association between APA and lymphoid neoplasm. The patient's unique presentation is in marked contrast to other reports of APA and lymphoid malignancy, which are typically associated with elevated PTT, normal PT, minimal extranodal disease, and potential thrombotic complications. Further, treatment with Rituximab-CHOP chemotherapy led to excellent clinical response with tumor remission and normalization of PT and PTT.

Entities:  

Keywords:  R-CHOP; antiphospholipid syndrome; coagulopathy; diffuse large cell lymphoma; lupus anticoagulant; sacral lesion; supratherapeutic INR

Mesh:

Substances:

Year:  2011        PMID: 22180680      PMCID: PMC3238310     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  8 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 2.  Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant.

Authors:  Y K Keung; E Cobos; G E Meyerrose; G H Roberson
Journal:  Leuk Lymphoma       Date:  1996-01

3.  Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma.

Authors:  I Genvresse; D Lüftner; E Späth-Schwalbe; F Buttgereit
Journal:  Eur J Haematol       Date:  2002-02       Impact factor: 2.997

4.  Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10- enzyme systems.

Authors:  A B Combs; T H Porter; K Folkers
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-01

5.  Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy.

Authors:  Eugene R Ahn; Gabriella Lander; Carlos J Bidot; Wenche Jy; Yeon S Ahn
Journal:  Am J Hematol       Date:  2005-02       Impact factor: 10.047

6.  Antiphospholipid antibodies in lymphoma: prevalence and clinical significance.

Authors:  Simona Pusterla; Sara Previtali; Stefana Marziali; Sergio Cortelazzo; Andrea Rossi; Tiziano Barbui; Monica Galli
Journal:  Hematol J       Date:  2004

7.  Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.

Authors:  Osnat Bairey; Dorit Blickstein; Yehudit Monselise; Judith Lahav; Pinhas Stark; Miron Prokocimer; Hila Magen Nativ; Ilia Kirgner; Idit Pazgal; Mati Shaklai
Journal:  Eur J Haematol       Date:  2006-02-06       Impact factor: 2.997

Review 8.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  8 in total
  1 in total

1.  Primary sacral non-Hodgkin's lymphoma: report of a case and systematic review of literature.

Authors:  Satya Vijay Chigurupati; Mridula Shukla; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2021-02-24       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.